Bexson Biomedical has a total of 22 patents globally, out of which 2 have been granted. Of these 22 patents, more than 77% patents are active. United States of America is where Bexson Biomedical has filed the maximum number of patents, followed by Europe and Canada. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Bexson Biomedical.
Bexson Biomedical was founded in the year 2016. The Company is developing a unique formulation of ketamine for chronic and acute pain disorders.
Do read about some of the most popular patents of Bexson Biomedical which have been covered by us in this article and also you can find Bexson Biomedical patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Bexson Biomedical patent portfolio.
How many patents does the founder and the CEO of Bexson Biomedical have?
The founder Jeffrey Becker has 30 patents and CEO Gregg Peterson has 29 patents.
How many patents does Bexson Biomedical have?
Bexson Biomedical has a total of 22 patents globally. These patents belong to 5 unique patent families. Out of 22 patents, 17 patents are active.
How Many Patents did Bexson Biomedical File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
Year of Patents Filing or Grant | Bexson Biomedical Applications Filed | Bexson Biomedical Patents Granted |
2022 | 1 | 1 |
2021 | 11 | 1 |
2020 | 6 | – |
2018 | 4 | – |
How many Bexson Biomedical patents are Alive/Dead?
How Many Patents did Bexson Biomedical File in Different Countries?
Countries in which Bexson Biomedical Filed Patents
Country | Patents |
United States Of America | 6 |
Europe | 5 |
Canada | 4 |
Japan | 1 |
China | 1 |
Where are Research Centres of Bexson Biomedical Patents Located?
The Research Centre for all the Bexson Biomedical patents is the United States of America.
What Percentage of Bexson Biomedical US Patent Applications were Granted?
Bexson Biomedical (Excluding its subsidiaries) has filed 3 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 2 have been granted leading to a grant rate of 100.0%.
Below are the key stats of Bexson Biomedical patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Bexson Biomedical?
Law Firm | Total Applications | Success Rate |
Wilson Sonsini Goodrich & Rosati | 3 | 100.00% |
List of Bexson Biomedical Patents
Bexson Biomedical Patents | Title |
US11534454B2 | Complexing Agent Salt Formulations Of Pharmaceutical Compounds |
US10973780B2 | Ketamine Formulation For Subcutaneous Injection |
US20230330328A1 | Systems And Devices For Controlled Drug Delivery |
US20230124101A1 | Complexing Agent Salt Formulations Of Pharmaceutical Compounds |
US20210186896A1 | Ketamine Formulation For Subcutaneous Injection |
US20200384188A1 | Systems, Devices, Formulations And Methods For Controlled Drug Delivery |
EP4247340A1 | Complexing Agent Salt Formulations Of Pharmaceutical Compounds |
EP4247386A1 | Flumazenil Formulations For Subcutaneous Injection And Methods Of Treatment Using Gaba Receptor Modulators |
EP4164711A2 | Systems And Devices For Controlled Drug Delivery |
EP3968979A4 | Ketamine Formulation For Subcutaneous Injection |
EP3710079A4 | Systems, Devices, Formulations And Methods For Controlled Drug Delivery |
CN114126596A | Ketamine Formulations For Subcutaneous Injection |
CA3198795A1 | Complexing Agent Salt Formulations Of Pharmaceutical Compounds |
CA3182097A1 | Systems And Devices For Controlled Drug Delivery |
CA3140046A1 | Ketamine Formulation For Subcutaneous Injection |
CA3082423A1 | Systems, Devices, Formulations And Methods For Controlled Drug Delivery |
JP2022533971A5 | Ketamine Formulation For Subcutaneous Injection |
WO2022109050A1 | Complexing Agent Salt Formulations Of Pharmaceutical Compounds |
WO2022109052A1 | Flumazenil Formulations For Subcutaneous Injection And Methods Of Treatment Using Gaba Receptor Modulators |
WO2021252971A3 | Systems And Devices For Controlled Drug Delivery |
WO2020232274A1 | Ketamine Formulation For Subcutaneous Injection |
WO2019099568A1 | Systems, Devices, Formulations And Methods For Controlled Drug Delivery |
What are Bexson Biomedical key innovation segments?
What Technologies are Covered by Bexson Biomedical?
The chart below distributes patents filed by Bexson Biomedical